Rituximab, in addition to other antibody therapies such as anti-GD2 and Trastuzumab (for neuroblastoma and Her-2+ breast cancer, respectively), bind to their cognate tumor antigens upon infusion into the patient. Here, ERBB2 is linked to breast cancer.